AMOEBA: directors' dealings · France · AMF

About AMOEBA

Amoéba is a French greentech company listed on Euronext Growth under ticker ALMIB, with ISIN FR0011051598. Founded in 2010 and headquartered in Chassieu, near Lyon, the company has built its strategy around a proprietary platform based on the industrial use of the naturally occurring amoeba Willaertia magna C2c Maky. Its mission is to develop natural microbiological solutions aimed at reducing microbiological risk across several high-potential end markets, at the crossroads of biotechnology, crop protection and cosmetics. The company initially gained recognition through a biological biocide for water treatment, then progressively expanded its scope toward agricultural biocontrol and cosmetic ingredients. Historically, Amoéba became known for its ability to develop an industrial process to cultivate the amoeba at scale, a capability it presents as unique worldwide. The company went public in 2015 and spent many years in R&D and pre-commercial development. Since 2023-2025, its profile has evolved as it has shifted strategically toward the markets with the best value creation potential and the shortest time to monetization. This repositioning was accompanied by a governance change in early 2024, with Benoit Villers appointed chairman and a stated objective of accelerating the path to positive operating cash flow. Amoéba’s main business lines are now agricultural biocontrol and cosmetics, both built on the same core technology based on amoeba lysate. From a regulatory standpoint, the company has achieved several major milestones: approval of its active substance in the United States, a final positive opinion from EFSA in Europe, then final approval of the active substance by the European Commission in June 2025 and U.S. market authorization for its AXPERA products in October 2025. In early 2026, Amoéba also announced its first commercial order with Koppert, which marked a clear step from development toward commercialization. Geographically, Amoéba remains firmly anchored in France, where its headquarters and production site are located in Chassieu, but its commercial strategy is international. The company is primarily targeting Europe and the United States as its initial launch markets and has indicated that it relies on distribution partners to support commercialization. It is positioned as a niche innovation-driven player with a long regulatory cycle but a strong differentiation profile, robust intellectual property and a compelling substitution narrative versus conventional chemical solutions. Recent capital increases in 2025 and 2026 were intended to fund the industrial and commercial scale-up.